AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.67-1.84 (-1.74%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.67-1.84 (-1.74%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|
12.4 C
New York
Sunday, November 1, 2026

Tag: design

newsFORsourcecompanycontentinformationreleases1market

Finnate Listed on PathFin.ai Knowledge Hub under the MAS Pathfinder Programme Following Independent Review and Verification Process

MAS Pathfinder Programme listing reflects Finnate's governance-focused design and real-world deployment maturity across regulated financial servicesMELBOURNE, Australia, June 8, 2026 /PRNewswire/ -- Centelon announced that...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale

MONROE, N.J. and RANCHO CUCAMONGA, Calif., June 7, 2026 /PRNewswire/ -- For 12 years, MimiSilk, the at-home beauty device brand, has remained committed to a single...

MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale

MONROE, N.J. and RANCHO CUCAMONGA, Calif., June 7, 2026 /PRNewswire/ -- For 12 years, MimiSilk, the at-home beauty device brand, has remained committed to a single...

A New Era Begins: Cal Poly Unveils the John Madden Football Center

$45 Million Facility Honors Legendary Alumnus and Elevates the Future of Mustang FootballSAN LUIS OBISPO, Calif., June 6, 2026 /PRNewswire/ -- Cal Poly Athletics...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

SKG Launches PS700 Neck Massager, Bringing Deep Kneading, Layered Heat, and Immersive Audio to Everyday Recovery

The new wearable recovery device pairs deep-kneading massage, layered warmth, and immersive audio to help ease neck tension 
The new wearable recovery device pairs deep-kneading massage, layered warmth, and immersive audio to help ease neck tension

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

Fox ESS Unveils Dynamic Energy Ecosystem Alongside Its First Rebrand Area at SNEC 2026

SHANGHAI, June 6, 2026 /PRNewswire/ -- Fox ESS, a global leader in renewable energy solutions, successfully concluded SNEC 2026 following the official launch of its...

Leading Vision Insurance for Glasses (2026): VSP Individual Vision Plans Named Top Plan for Frames and Lens Coverage by Better Business Advice

NEW YORK, June 6, 2026 /PRNewswire/ -- VSP® Individual Vision Plans has been recognized by Better Business Advice as a top vision insurance option...

CST Tires Showcases Lightweight Innovation at 2026 China International Bicycle Expo

SHANGHAI, June 5, 2026 /PRNewswire/ -- Recently, the highly anticipated 34th China International Bicycle Exhibition (CHINA CYCLE) concluded successfully at the Shanghai New International...

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDesign

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers